Compare TRIP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRIP | DRTS |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Computer Software: Programming Data Processing | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 978.2M |
| IPO Year | 2011 | N/A |
| Metric | TRIP | DRTS |
|---|---|---|
| Price | $14.55 | $11.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $14.40 | $8.67 |
| AVG Volume (30 Days) | ★ 2.6M | 803.0K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,556,000,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $5.12 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.01 | $2.87 |
| 52 Week High | $20.16 | $14.11 |
| Indicator | TRIP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 43.80 |
| Support Level | $13.04 | $6.59 |
| Resistance Level | $15.33 | $11.48 |
| Average True Range (ATR) | 0.57 | 0.91 |
| MACD | -0.08 | -0.23 |
| Stochastic Oscillator | 75.41 | 1.19 |
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.